Hypertension Treatment and Control in a New York City Health Care System

April-Sanders, Ayana; Golestaneh, Ladan; Zhang, Lili; Swett, Katrina; Meißner, Paul; Rodríguez, Carlos J.

doi:10.1161/jaha.122.026077

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the national level, there were signi cant differences in the ASPR of HHD in WCBA across countries and regions, emphasizing the strong heterogeneity of the global burden of HHD in WCBA. This trend can be attributed to various factors, including genetics (17), exposure to risk factors (18), customs and habits (19), and the prevalence of healthcare systems (20). Wealth or income with its unequal distribution and potentially having signi cant adverse impacts on health nancing, access to healthcare and outcomes (21).…”

Section: Discussionmentioning

confidence: 99%

Temporal Trends in the Prevalence of Hypertensive Heart Disease in Women of Childbearing Age Over 30 Years

Hu,

Wang,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Aim Epidemiological research on hypertensive heart disease (HHD) in women of childbearing age (WCBA) remains scarce. Our objective is to describe the current prevalence of HHD in WCBA at global, regional, and national levels and to analyze its temporal trends from 1990 to 2019. Methods WCBA was defined as women aged 15–49 years. Estimates and 95% Uncertainty Intervals (UI) of HHD prevalence numbers for seven age groups (15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49 years) were extracted from the 2019 Global Burden of Disease Study (GBD). The age-standardized prevalence rate (ASPR) of HHD in WCBA was estimated using the direct age-standardization method. Joinpoint regression analysis was used to calculate the Annual Percentage Change (APC) and Average APC (AAPC) along with their 95% Confidence Intervals (CI), analyzing the temporal trends from 1990 to 2019. Results In 1990 and 2019, the global ASPR of HHD in WCBA was 23.20 (95% UI: 12.72 to 38.43) and 23.67 (95% UI: 13.02 to 38.73), respectively, with high Socio-Demographic Index (SDI) regions generally exhibiting higher ASPRs than other regions. From 1990 to 2019, there was a significant global increase in HHD WCBA (AAPC = 0.08%, 95% CI:0.03 to 0.12; P < 0.001), with notable increases in high-middle SDI region (AAPC = 0.78%, 95%CI: 0.69 to 0.88; P < 0.001), middle SDI region (AAPC = 0.32%, 95%CI: 0.27 to 0.37; P < 0.001), low-middle SDI region (AAPC = 0.50%, 95%CI: 0.44 to 0.56; P < 0.001), and low SDI region (AAPC = 0.36%, 95%CI: 0.34 to 0.37; P < 0.001). However, HHD in high SDI regions significantly decreased (AAPC = -0.52%, 95% CI: -0.74 to -0.31; P < 0.001). The most significant changes occurred in different periods. The ASPR trends of HHD in WCBA varied greatly among 204 countries and territories. Conclusions Between 1990 and 2019, there was strong heterogeneity in the ASPR of HHD in WCBA globally and in its temporal trends (1990–2019). The ASPR decreased in high SDI regions but continuously increased in low SDI regions. These findings highlight the stark global disparities in HHD among WCBA, with significant implications for the equitable allocation of medical resources and the formulation of relevant health policies.

show abstract

Section: Discussionmentioning

confidence: 99%

Temporal Trends in the Prevalence of Hypertensive Heart Disease in Women of Childbearing Age Over 30 Years

Hu,

Wang,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…A similar effect was observed when both IPP and LKP CZ NP were administered by oral gavage in the SHR rat model. Captopril is an oral antihypertensive drug which has as a single oral dose effective for 6–8 h. Clinical use requires a dose of 37–75 mg of captopril to be taken three times daily [ 4 ]. Hence, LKP/IPP CZ NP were tested over 8 h. The results presented for free IPP and LKP showed a reduction in blood pressure for only the first 3 h of administration.…”

Section: Discussionmentioning

confidence: 99%

“…ACE inhibitors are essential in the treatment for both high and low risk hypertension, and combination therapies such as “polypill” incorporate ACE inhibitors (enalapril) along with non-steroidal anti-inflammatory drugs (NSAID; aspirin), statins (atorvastatin) and diuretics (hydrochlorothiazide) [ 4 , 5 ]. Captopril, an ACE inhibitor, is a US Food Drug and Administration approved medication to manage primary hypertension.…”

Section: Introductionmentioning

confidence: 99%

Formulation, Characterisation and Evaluation of the Antihypertensive Peptides, Isoleucine-Proline-Proline and Leucine-Lysine-Proline in Chitosan Nanoparticles Coated with Zein for Oral Drug Delivery

Danish

Gleeson

Brayden

et al. 2022

IJMS

View full text Add to dashboard Cite

Isoleucine-Proline-Proline (IPP) and Leucine-Lysine-Proline (LKP) are food-derived tripeptides whose antihypertensive functions have been demonstrated in hypertensive rat models. However, peptides display low oral bioavailability due to poor intestinal epithelial permeability and instability. IPP and LKP were formulated into nanoparticles (NP) using chitosan (CL113) via ionotropic gelation and then coated with zein. Following addition of zein, a high encapsulation efficiency (EE) (>80%) was obtained for the NP. In simulated gastric fluid (SGF), 20% cumulative release of the peptides was achieved after 2 h, whereas in simulated intestinal fluid (SIF), ~90% cumulative release was observed after 6 h. Higher colloidal stability (39–41 mV) was observed for the coated NP compared to uncoated ones (30–35 mV). In vitro cytotoxicity studies showed no reduction in cellular viability of human intestinal epithelial Caco-2 and HepG2 liver cells upon exposure to NP and NP components. Administration of NP encapsulating IPP and LKP by oral gavage to spontaneously hypertensive rats (SHR) attenuated systolic blood pressure (SBP) for 8 h. This suggests that the NP provide appropriate release to achieve prolonged hypotensive effects in vivo. In conclusion, chitosan-zein nanoparticles (CZ NP) have potential as oral delivery system for the encapsulation of IPP and LKP.

show abstract

“…While health care systems are known to be highly incentivized to provide care for acute illnesses such as myocardial infarction and stroke, they are not well designed for preventive care (1)(2)(3). Primary prevention of cardiovascular disease may potentially be better managed in a system non-centered on the acute care model (4)(5)(6). Hence, it is time to acknowledge that standard strategies for blood pressure (BP) management in clinical practice are failing to achieve ideal BP control rates (7)(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

The therapeutic concordance approach reduces adverse drug reactions in patients with resistant hypertension

Trimarco

Manzi

Izzo

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAdverse drug reactions (ADRs) remain among the leading causes of therapy-resistant hypertension (TRH) and uncontrolled blood pressure (BP). We have recently reported beneficial results in BP control in patients with TRH adopting an innovative approach, defined as therapeutic concordance, in which trained physicians and pharmacists reach a concordance with patients to make them more involved in the therapeutic decision-making process.MethodsThe main scope of this study was to investigate whether the therapeutic concordance approach could lead to a reduction in ADR occurrence in TRH patients. The study was performed in a large population of hypertensive subjects of the Campania Salute Network in Italy (ClinicalTrials.gov Identifier: NCT02211365).ResultsWe enrolled 4,943 patients who were firstly followed-up for 77.64 ± 34.44 months, allowing us to identify 564 subjects with TRH. Then, 282 of these patients agreed to participate in an investigation to test the impact of the therapeutic concordance approach on ADRs. At the end of this investigation, which had a follow-up of 91.91 ± 54.7 months, 213 patients (75.5%) remained uncontrolled while 69 patients (24.5%, p < 0.0001) reached an optimal BP control. Strikingly, during the first follow-up, patients had complained of a total of 194 ADRs, with an occurrence rate of 68.1% and the therapeutic concordance approach significantly reduced ADRs to 72 (25.5%).ConclusionOur findings indicate that the therapeutic concordance approach significantly reduces ADRs in TRH patients.

show abstract

Hypertension Treatment and Control in a New York City Health Care System

Cited by 6 publications

References 5 publications

Temporal Trends in the Prevalence of Hypertensive Heart Disease in Women of Childbearing Age Over 30 Years

Temporal Trends in the Prevalence of Hypertensive Heart Disease in Women of Childbearing Age Over 30 Years

Formulation, Characterisation and Evaluation of the Antihypertensive Peptides, Isoleucine-Proline-Proline and Leucine-Lysine-Proline in Chitosan Nanoparticles Coated with Zein for Oral Drug Delivery

The therapeutic concordance approach reduces adverse drug reactions in patients with resistant hypertension

Contact Info

Product

Resources

About